GlaxoSmithKline PLC plans over a three-year period to move its Costa Rica manufacturing operation to production capacity available in other sites of its network in Latin America while keeping its Pharmaceutical and Consumer Healthcare divisions and its Business Services Center in the country. The UK pharma firm on Feb. 23 said it will transfer production and packaging of Eno antacid effervescent sachets and Panadol (paracetamol [acetaminophen]) liquid products to other sites. Glaxo, which markets its and Novartis AG’s consumer health care products in a joint venture, GSK Consumer Healthcare LP, said it will transfer the product lines manufactured in San Jose, Costa Rica, in a process that will begin this year and end in 2019, closing a site that has been producing and supplying multiple products for more than 60 years. Manufacturing will continue at the site until all product lines are transferred to other GSK sites in multiple phases.
Glaxo said it will review the possibility of relocating the facility’s 150 employees to other operations and other manufacturing companies...
